Clinical trial
A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)
NCT01021956 is registered in ClinicalTrials.gov with Steba Biotech S.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)
- Lead sponsor
- Steba Biotech S.A.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- June 30, 2010
- Completion date
- January 31, 2014
- Enrollment
- 10 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.